FDA Releases Final Guidance on Risk-Based Monitoring of Clinical Investigations

Summary

The FDA has released a final guidance for industry on risk-based monitoring of clinical investigations for human drug and biological products, medical devices, and combination products, building on previous guidance and providing additional information to facilitate sponsors' implementation of risk-based monitoring.